**Case Report**

**Cerebral toxoplasmosis in a patient with combined variable immunodeficiency**

Torrey Czech1, Parthav Shah1, Gunnar Lee2, Gina Watanabe3, Christian Ogasawara3, Thomas Noh4

1Department of Internal Medicine, University of Hawaii John A. Burns School of Medicine, Departments of 1Neurological Surgery, 2Medicine, 3Neurosurgery, John A. Burns School of Medicine, Honolulu, Hawaii, United States.

E-mail: Torrey Czech - tczech@hawaii.edu; *Parthav Shah - parthavs@hawaii.edu; Gunnar Lee - keeg3@hawaii.edu; Gina Watanabe - ginaw@hawaii.edu; Christian Ogasawara - cogasawa@hawaii.edu; Thomas Noh - thomas.noh@gmail.com

**ABSTRACT**

Background: Cerebral toxoplasmosis is an opportunistic infection in patients but has rarely been described in the setting of compromised humoral immunodeficiency. Prompt diagnosis and treatment of the infection is critical in the care of these patients. Medical management is the mainstay of treatment of the infection. There have been very few reports of surgical management of cerebral toxoplasmosis.

Case Description: We describe the case of a 40-year-old male who presented with headache, memory deficits, weight loss, and left-sided weakness in the setting of a known but undiagnosed brain lesion identified 1 month prior. Imaging demonstrated a right basal ganglia lesion which was initially presumed to be malignancy. On further workup including a positive serum test and biopsy including polymerase chain reaction analysis, diagnosis was confirmed as toxoplasmosis. On further investigation, he was found to have deficiencies in immunoglobulins consistent with common variable immunodeficiency (CVID). The patient underwent craniotomy with surgical debulking as repeat imaging showed increased size of mass with new satellite lesions and worsening hydrocephalus.

Conclusion: Cerebral toxoplasmosis is an important differential to consider in cases of intracerebral lesions and should not necessarily be excluded in the absence of compromised cellular immunity. In cases where there is no immunocompromised state and malignancy cannot immediately be established, CVID should be considered as an etiology. Due to the subtlety of CVID diagnosis, careful attention should be paid to history taking and workup for CVID should be considered as soon as possible. Surgical removal of these lesions in conjunction with medications is an effective treatment option.

Keywords: Cerebral toxoplasmosis, Common variable immunodeficiency, Craniotomy, Surgical debulking

**INTRODUCTION**

Cerebral toxoplasmosis is a life-threatening infection caused by reactivation of the protozoan parasite *Toxoplasma gondii* in primarily immunocompromised individuals. Cerebral toxoplasmosis is typically included in the differential for patients with a history of human immunodeficiency virus (HIV) infection, bone marrow transplant, or other immunosuppressive conditions. Clinical presentation varies widely in regard to the nature of onset and neurological deficit. A presumptive diagnosis in immunocompromised individuals can be made based on the clinical presentation, observing multiple ring-enhancing lesions on computed tomography (CT)
or magnetic resonance imaging (MRI), and positive serological testing. However, the presence of undiagnosed immunodeficiencies and solitary radiographic lesions can lead to delays in toxoplasmosis diagnosis and increasing involvement of neurosurgical specialists.

Common variable immunodeficiency (CVID) is an often underdiagnosed primary immune deficiency characterized by impaired B-cell differentiation, leading to decreased serum levels of immunoglobulin (Ig)G, IgA, and/or IgM. The presentation of CVID is heterogeneous making it a diagnostic challenge. Most cases present as recurrent sinopulmonary tract infections, though inflammatory and autoimmune manifestations such as autoimmune cytopenia, enteropathy, and chronic lung disease have been reported in more than a fifth of CVID patients. Toxoplasmosis is prevalent in people with compromised cellular immunity, but it is unusual in people with humoral immune deficiency. There have been a few rare case reports of people with CVID developing cerebral toxoplasmosis and of nonbiopsy neurosurgical management of cerebral toxoplasmosis. Herein, we describe the clinical course and surgical management of a 40-year-old patient with cerebral toxoplasmosis who was later diagnosed with CVID.

CASE REPORT

A 40-year-old Caucasian male with a 2-month history of headache, memory problems, weight loss, chronic diarrhea, and arthralgias, presented to an outside hospital with new-onset significant left-sided weakness impacting his ability to perform his activities of daily living. Medical history was remarkable for recurrent sinus infections and recurrent otitis media. He had no family history of central nervous system diseases or immunologic disease. CT head demonstrated an ill-defined mass in the right gangliocapsular region and midbrain and approximately 10 mm of leftward subfalcine herniation. MRI demonstrated a 4.4 × 2.4 × 4.5 cm right basal ganglia lesion with extension into midbrain, peripheral enhancement with extensive surrounding edema, and 7 mm midline shift [Figure 1]. CT abdomen pelvis revealed reticulonodular infiltrates of the right and left lower lobes, splenomegaly with mesenteric lymphadenopathy. The patient underwent retroperitoneal CT-guided lymph node biopsy which showed no malignancy. A small bowel push enteroscopy noted acute duodenitis and mild villous blunting. He was seen by an oncologist who suspected his case was consistent with lymphoma or unspecified malignancy and started the patient on steroids. Infectious disease doctor ordered AFB and fungal studies.

He then presented to our hospital with worsening weakness. On examination, he had 0/5 strength on his left upper extremity, left side facial droop, midline palatal elevation, midline tongue protrusion, and right-sided ptosis. Laboratory tests on admission are summarized in Table 1, and they were all within the normal range aside from a leukocytosis to 24.5 × 10^9/L. CSF studies showed low glucose, low protein, negative for cryptococcus, and streptococcus. Serum Toxoplasma IgM was reactive and IgG was reactive at 17.4. Negative studies included HIV antibody (Ab), rapid plasma regain, Treponema pallidum particle agglutination assay, cytomegalovirus IgM, Rickettsia Ab, Brucella Ab, Bartonella Ab, antinuclear antibody, anti-neutrophil cytoplasmic antibody, urine legionella, and pneumococcal antigens. A brain biopsy was performed where four biopsy specimens were obtained at 90° angles and another four biopsy specimens 1 cm deeper were taken in a similar fashion. Pathology was consistent with a histiocyte predominant neuroinflammatory process [Figure 2]. Postoperatively, the patient had no neurological changes.

One week later, despite being on antibiotics and antifungals, his neurological examination deteriorated and he became more obtunded and less responsive. A repeat MRI showed an increase in size of mass with new satellite lesions and hydrocephalus. The decision was made to perform a craniotomy for excision of enlarging mass to debulk and obtain tissue specimens for diagnosis.

During the operation, there was a tough rind that was encountered and dissected around. Initial specimens did not indicate any obvious tumor, and thus, a pericapsular

![Figure 1: Magnetic resonance imaging brain demonstrating a large, 56 × 40 mm isolated lesion and presence of midline shift.](image_url)
dissection was continued until most of the mass was removed with a small rind left around the midbrain. Specimen was sent for pathology, culture, and analysis. Postoperatively, he was intubated but opened his eyes to voice and followed commands on his right side. He was extubated on POD 7 and was AO × 3 with dense left hemiplegia. Polymerase chain reaction analysis of the mass was positive for toxoplasmosis gondii [Figure 3]. He was treated with meropenem, pyrimethamine, leucovorin, and atovaquone for 2 months due to a sulfa allergy. One month postoperatively, an MRI brain showed shrinking residual enhancement. He was discharged on hospital day 60. Following the hospitalization, the patient was referred to an allergy and immunology specialist for undetectable Ig levels consistent with severe panhypoglobulinemia with IgG <109, IgA, and IgM <5 mg/dL that was found during his hospitalization. The patient was diagnosed with CVID and was started on IVIG replacement therapy. He continued to improve and was able to mobilize feet in a wheelchair 4 months after surgery and had his suprapubic catheter removed. At 6 months, he was opening his right eye again and started to move his left lower extremity. He also passed his swallow study and had weaned off of tube feeds. Seven months postoperatively, he unexpectedly passed at home from sudden cardiac arrest.

DISCUSSION

Cerebral toxoplasmosis is caused by T. gondii, a ubiquitous obligate intracellular parasite.\(^7\) T. gondii is transmitted vertically, zoonotically, through organ transplantation, or by ingesting contaminated food or water. In the United States, it is estimated that T. gondii has infected 11% of the population aged 6 and older. One-third of all HIV-infected people demonstrate positive T. gondii IgG serology.\(^5,13\)

Cerebral toxoplasmosis is an opportunistic disease seen in patients with a compromised cellular immunity. Interferon-dependent, CD8+ T cell-mediated immunity is the mainstay of resistance against cerebral toxoplasmosis.\(^25\) Notably, our patient did not have a deficit of cellular immunity; he was found to have a deficiency of Ig, thus causing a humoral immune deficiency. CVID is a primary immunodeficiency characterized by lack of B-cell differentiation, which causes

**Table 1:** Laboratory values from admission and cerebrospinal fluid analysis.

| Complete blood count | CSF |
|----------------------|-----|
| WBC (10⁹/L)          | 21  |
| Hb (g/dl)            | 15.8|
| Hct (%)              | 47.8|
| Plt (10⁹/L)          | 170 |
| Neutrophils (%)      | 46  |
| Lymphocytes (%)      | 36  |
| Monocytes (%)        | 17  |
| Macrophages (%)      | 1   |
| Glucose (%)          | 56  |
| Total protein        | 91  |
| Phosphorus (mg/dL)   | 5.2 |
| Mg (mg/dL)           | 2.1 |
| Glucose (mg/dL)      | 136 |
| BUN (mg/dL)          | 17  |
| S. Cr (mg/dL)        | 0.55|
| Alb (mg/dL)          | 4.3 |
| AST (IU/L)           | 28  |
| ALT (IU/L)           | 53  |
| ALP (IU/L)           | 151 |
| T. Bil (mg/dL)       | 0.4 |

Hb: Hemoglobin, WBC: White blood cell, Hct: Hematocrit, Plt: Platelet, Na: Sodium, K: Potassium, Cl: Chloride, Ca: Calcium, Mg: Magnesium, S.Cr: Serum creatinine, Alb: Albumin, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase, T-Bil: Total bilirubin, CSF: Cerebrospinal fluid, RBC: Red blood cell, VDRL: Venereal disease research laboratory, Strep pneumo: *Streptococcus pneumoniae*
defective Ig production resulting in hypogammaglobulinemia. It often becomes clinically apparent in the third or fourth decade of life, as seen in our patient. This defect in humoral immunity typically leads to recurrent bacterial infections. Sometimes, there is a delay in diagnosing these patients as was the case in our patient. He had a history of recurrent ear infections, but he was unfortunately never diagnosed with CVID despite being worked up. There is a lack of literature regarding the prevalence of toxoplasmosis in patients with CVID. There have been a few case reports of cerebral toxoplasmosis in CVID patients reported in the literature. However, none of those patients underwent surgical debulking.[1,12,21] Interestingly, only one such patient had a defect in humoral immunity without a defect in cellular immunity.[12] The patient was a 52-year-old female who was diagnosed with toxoplasmosis while being on treatment for CVID. The exact mechanism of toxoplasmosis in patients with humoral immune deficiency is unclear. Experimental data in mice have shown that a reduction of antibody-producing B-cells decreases the resistance against *T. gondii.*[14] In addition, the treatment of B-cell deficient mice with antibodies reduced mortality and prolonged survival.[23] It is important for physicians to keep toxoplasmosis in the differential when treating a patient with humoral immunodeficiency who presents with intracerebral mass lesions. In our case, the patient was diagnosed with toxoplasmosis before being diagnosed with CVID. Large-scale studies are required to determine the prevalence of toxoplasmosis in patients with humoral immunodeficiencies to determine if workup for these diseases should be included in all patients with toxoplasmosis.

One rare component of this case was the presentation of cerebral toxoplasmosis as a large solitary lesion, initially thought to be more characteristic of a primary brain malignancy. Given the solitary lesion and presence of enlarged lymph nodes, a presumptive diagnosis of lymphoma was made which contributed to a delay in diagnosis and treatment of the toxoplasmosis. Solitary lesions in an immunocompromised patient are more likely associated with either primary central nervous system (CNS) lymphoma in higher-income countries or tuberculomas in the developing countries.[6,20] The majority of cases of toxoplasmosis present with multiple small ring-enhancing lesions. Imaging can be used to differentiate toxoplasmosis and CNS lymphoma. However, there is a radiologic overlap between the two. Certain features such as number of lesions (multiple in toxoplasmosis vs. single in lymphoma) and location (basal ganglia in toxoplasmosis vs. brain periphery or corpus callosum for lymphoma) can help differentiate the two.[6] Perfusion MRI can allow for distinction between the two, with lymphoma lesions showing hypervascularity and increased blood volume.[16] However, in some cases, it is difficult to differentiate the two radiographically if they do not have the classic features on imaging. Stereotactic biopsy is warranted for definite diagnosis in those cases. Stereotactic biopsy is an effective procedure with diagnostic success rates as high as 98% with low rates of complications.[15,29]

Early presumptive diagnosis and empirical treatment are crucial to the management of cerebral toxoplasmosis. However, the absence of an existing immunosuppressive diagnosis as well as atypical radiographic features may delay appropriate treatment including surgery. The previous studies have shown that patients on medical management experience CNS response in 5 days and about 95% of patients show radiographic improvement by day 14 of treatment.[16,20] Here, we present a case where the patient underwent craniotomy with surgical debulking. Depressive craniectomies for infectious encephalitis of other etiologies including herpes simplex virus, *Mycoplasma pneumoniae,* and unidentified viral infection have been described in the literature.[2] Lesional resection of cerebral toxoplasmosis has only been reported a few times in the literature.[1,3,19] *Toxoplasma* can cause complications like obstructive hydrocephalus due to ventriculitis or compression and blockage of the ventricular system without response to treatment.[4,6,24] In all of these cases, resection was performed due to worsening clinical status and, in all cases, patients died. At present, no guidelines exist to direct surgical management for cerebral toxoplasmosis. More studies are needed to determine the outcomes of earlier surgical resection in medically refractory patients.

**CONCLUSION**

We described a patient of cerebral toxoplasmosis with CVID who underwent craniotomy with surgical debulking. In our patient, the patient was initially diagnosed with cerebral toxoplasmosis before being diagnosed with CVID. Although cerebral toxoplasmosis is often associated with HIV, the diagnosis should be included in the differential for any individual with suspected or confirmed immunodeficiency. It should be suspected in patients with humoral immunodeficiency along with cell-mediated immunodeficiency. Furthermore, clinicians should look for undiagnosed immunodeficiency in patients with confirmed diagnosis of cerebral toxoplasmosis. Accurate diagnosis can be challenging especially when in cases, where the immunodeficiency is undiagnosed and radiologic imaging studies demonstrate a solitary lesion as it was seen in our case, which can lead to a delay in treatment.

**Declaration of patient consent**

The authors certify that they have obtained all appropriate patient consent.

**Financial support and sponsorship**

Nil.
Czech, et al.: Cerebral toxoplasmosis in a patient with combined variable immunodeficiency

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Abbasi Fard S, Khajeh A, Khosravi A, Mirshekar A, Masoumi S, Tabasi F, et al. Fulminant and diffuse cerebral toxoplasmosis as the first manifestation of HIV infection: A case presentation and review of the literature. Am J Case Rep 2020;21:e919624.

2. Adamo MA, Deshaies EM. Emergency decompressive craniectomy for fulminating infectious encephalitis. J Neurosurg 2008;108:174-6.

3. Agrawal D, Hussain N. Decompressive craniectomy in cerebral toxoplasmosis. Eur J Clin Microbiol Infect Dis 2005;24:772-3.

4. Basavaprabhu A, Soundarya M, Deepak M, Satish R. CNS toxoplasmosis presenting with obstructive hydrocephalus in patients of retroviral disease—a case series. Med J Malaysia 2012;67:214-6.

5. Basavaraaju A. Toxoplasmosis in HIV infection: An overview. Trop Parasitol 2016;6:129-35.

6. Ciricillo SF, Rosenblum ML. Use of CT and MR imaging to distinguish intracranial lesions and to define the need for biopsy in AIDS patients. J Neurosurg 1990;73:720-4.

7. Dalimi A, Abdoli A. Latent toxoplasmosis and human. Iran J Parasitol 2012;7:1-17.

8. Eggers C, Vortmeyer A, Emsköetter T. Cerebral toxoplasmosis in a patient with the acquired immunodeficiency syndrome presenting as obstructive hydrocephalus. Clin Neuropathol 1995;14:51-4.

9. Erdag N, Bhorade RM, Alberico RA, Yousuf N, Patel MR. Primary lymphoma of the central nervous system: Typical and atypical CT and MR imaging appearances. AJR Am J Roentgenol 2001;176:1319-26.

10. Ernst TM, Chang L, Witt MD, Aronow HA, Cornford ME, Walot I, et al. Cerebral toxoplasmosis and lymphoma in AIDS: Perfusion MR imaging experience in 13 patients. Radiology 1998;208:663-9.

11. Hofmann A, Zaharatos G, Miller M. Case report and review of the literature: Toxoplasma gondii encephalitis in a 40-year-old woman with common variable immunodeficiency and a new diagnosis of large granular lymphocytic leukemia. Can J Infect Dis Med Microbiol 2008;19:309-10.

12. Holtkamp M, Okuducu AF, Klingebiel R, Ploner CJ. Cerebral toxoplasmosis in a patient with common variable immunodeficiency. Neurology 2004;63:2192-3.

13. Jones JI, Kruzon-Moran D, Elder S, Rivera HN, Press C, Montoya JG, et al. Toxoplasma gondii Infection in the United States, 2011-2014. Am J Trop Med Hyg 2018;99:551-7.

14. Kang H, Remington JS, Suzuki Y. Decreased resistance of B cell-deficient mice to infection with Toxoplasma gondii despite unimpaired expression of IFN-gamma, TNF-alpha, and inducible nitric oxide synthase. J Immunol 2000;164:2629-34.

15. Lee AM, Bai HX, Zou Y, Qiu D, Zhou J, Martinez-Lage Alvarez M, et al. Safety and diagnostic value of brain biopsy in HIV patients: A case series and meta-analysis of 1209 patients. J Neurol Neurosurg Psychiatry 2016;87:722-33.

16. Luft BJ, Hafner R, Korzun AH, Leport C, Antonisiks D, Bosler EM, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 study team. N Engl J Med 1993;329:995-1000.

17. Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992;15:211-22.

18. Malphettes M, Gérard L, Carmagnat M, Mouillot G, Vince N, Boutboul D, et al. Late-onset combined immune deficiency: A subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis 2009;49:1329-38.

19. Manwani N, Ravikumar K, Viswanathan V, Rao SM, Mahadevan A. Acquired toxoplasmosis presenting with a brainstem granuloma in an immunocompetent adolescent. Indian Pediatr 2016;53:159-61.

20. Modi M, Mohan A, Modi G. Management of HIV-associated focal brain lesions in developing countries. Qjm 2004;97:413-21.

21. Mrusek S, Marx A, Kummerle-Deschner J, Tzaribachev N, Enders A, Riede UN, et al. Development of granulomatous common variable immunodeficiency subsequent to infection with Toxoplasma gondii. Clin Exp Immunol 2004;137:578-83.

22. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992;327:1643-8.

23. Sayles PC, Gibson GW, Johnson LL. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun 2000;68:1026-33.

24. Sell M, Klingebiel R, Di Iorio G, Sampaolesi S. Primary cerebral toxoplasmosis: A rare case of ventriculitis and hydrocephalus in AIDS. Clin Neuropathol 2005;24:106-11.

25. Suzuki Y, Orellana MA, Schreiber RD, Remington JS. Interferon-gamma: The major mediator of resistance against Toxoplasma gondii. Science 1988;240:516-8.

26. Tam JS, Routes JM. Common variable immunodeficiency. Am J Rhinol Allergy 2013;27:260-5.

27. Tenter AM, Heckeroth AR, Weiss LM. Toxoplasma gondii: From animals to humans. Int J Parasitol 2000;30:1217-58.

28. Vidal JE. HIV-related cerebral toxoplasmosis revisited: Current concepts and controversies of an old disease. J Int Assoc Provid AIDS Care 2019;18:232595821987315.

29. Zhang J, Liu X, Fu K, Xu C, Gong R, Liu L, et al. Diagnostic value and safety of stereotactic biopsy in acquired immune deficiency syndrome patients with intracranial lesions: Systematic review and meta-analysis. World Neurosurg 2017;98:790-9.e713.